Category: misconduct investigations

Science flags immune-boosting paper under investigation

F1.mediumScience magazine has issued an expression of concern for a paper on the discovery of a new immune-boosting protein. The paper’s findings, which received some press coverage when they came out last spring, are now under investigation by Imperial College London.

The expression of concern follows a correction noting a Western blot mix-up. Science Editor in Chief Marcia McNutt told us last month that the mistake resulted from “carelessness” on the part of the authors. But now, an investigation at Imperial College London — where Philip Ashton-Rickardt led the research — is formally looking into the findings.

That investigation is ongoing, according to the expression of concern (signed by McNutt):

Continue reading Science flags immune-boosting paper under investigation

Authors retract abstract following misconduct by diabetes biotech

1Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.

The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.

A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.

Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal:

Continue reading Authors retract abstract following misconduct by diabetes biotech

Cancer researcher cleared of misconduct, inquiry finds “genuine error or honest oversight”

Khachigian
Levon Khachigian

An investigation at the University of New South Wales in Australia has determined that a long-accused cancer researcher did not commit misconduct.

The investigation did find instances when Levon Khachigian breached the code of conduct, but Continue reading Cancer researcher cleared of misconduct, inquiry finds “genuine error or honest oversight”

Singapore investigation leads to two retractions, two more on the way

cov150hAuthors have retracted papers from Cell Metabolism and the Journal of Biological Chemistry after an investigation in Singapore found issues, including falsified data. The investigation is ongoing, and two additional retractions, along with two corrections, are on the horizon.

The investigation looked into papers by first authors Sudarsanareddy Lokireddy, now a postdoc at Harvard, and Sandhya Sriram, a postdoc at the Agency for Science, Technology and Research in Singapore. Led by the Nanyang Technological University in Singapore, where some of the work was done, the investigation concluded that there were issues with six papers on which either Sriram or Lokireddy was first author.

All authors but Lokireddy have agreed to retractions or corrections. Ravi Kambadur of NTU, and Mridula Sharma at the National University of Singapore, are the last two authors on all the papers.

According to a notice from the NTU, the “investigation found a number of instances of alterations to data” in three papers on which Lokireddy is first author. One of those was retracted December 1 by Cell Metabolism: Continue reading Singapore investigation leads to two retractions, two more on the way

7th retraction for heart researcher who faked patient records

1.coverAnna Ahimastos, a heart researcher who faked patient records, has notched her 7th retraction.

One more paper is expected to be retracted, according to a spokesperson from her former institution, the Baker IDI Heart & Diabetes Institute in Australia.

As with the other retractions, the 2005 paper in Hypertension — about how the hypertension drug ramipril may help alleviate cardiovascular disease — is being pulled after Ahimastos admitted to scientific misconduct. She asserts the data remain valid, and has not signed the retraction notice.

The Hypertension paper has been cited 63 times, according to Thomson Scientific’s Web of Knowledge. Here’s the retraction note in full (the language will be familiar to readers who have been following this case):

Continue reading 7th retraction for heart researcher who faked patient records

Cancer researcher contributed “false data” to 11 studies

ori-logoA former cancer researcher has falsified data in 11 studies, according to the results of a investigation scheduled to be published in the Federal Register tomorrow.

The Office of Research Integrity’s findings are based on an inquiry at Virginia Commonwealth University, where Girija Dasmahapatra worked until July of this year, investigating possible therapies for cancer. The misconduct affected research funded by three grants from the National Institutes of Health. Steven Grant, a researcher at VCU, is the principal investigator on the grants, each of which total over $2 million in funding. All of the 11 affected papers will be corrected or retracted, according to the ORI notice.

Two of the papers containing “falsified and/or fabricated” data — a study on an experimental combination of drugs for blood cancer and one on chemotherapies for rare forms of lymphoma  — were covered in press releases by VCU.

According to the notice in the Federal Register:

Continue reading Cancer researcher contributed “false data” to 11 studies

Investigation into CT scan paper reveals plagiarism

Screen Shot 2015-12-01 at 10.02.20 AMA paper on the quality of computed tomography (CT) images of the human body didn’t stand up to a close examination. It’s been retracted after an investigation found that it plagiarized work from two publications and a poster by another researcher.

The text in the Journal of the Korean Physical Society paper was taken from work by Kenneth Weiss, a radiologist at the University of Miami, and Jane Weiss, CFO of the couple’s medical imaging company. According to emails that Jane Weiss forwarded to us, Kenneth Weiss brought the plagiarism to light after a PhD student pointed out the similarities between the JKPS paper and one of Weiss’s in the American Journal of Roentgenology. Weiss notified the AJR in January. They started an investigation into the matter, and alerted the JKPS.

The retraction note for “Measurement of image quality in CT images reconstructed with different kernels” provides more details about the investigation:

Continue reading Investigation into CT scan paper reveals plagiarism

Diederik Stapel now has 58 retractions

stapel_npcSocial psychologist Diederik Stapel has notched his 58th retraction, after admitting he fabricated data in yet another article.

He’s holding onto his 4th place spot on our leaderboard.

This latest retraction is for “Correction or comparison? The effects of prime awareness on social judgments,” published in the European Journal of Social Psychology. As usual for Stapel, this paper has been retracted because he fabricated data.

Here’s the note:

Continue reading Diederik Stapel now has 58 retractions

My life as a whistleblower: Q&A with Peter Wilmshurst

We’re presenting a Q&A session with Peter Wilmshurst, now a part-time consultant cardiologist who has spent decades embroiled in misconduct investigations as a whistleblower.

Dr-Peter-Wilmshurst-007
Peter Wilmshurst

Retraction Watch: A UK judge recently upheld two findings of dishonesty by the Medical Practitioners Tribunal Service against Andrew Dowson, director of headache services at King’s College Hospital and your former co-investigator. Were you pleased with the verdict? (Last week, Dowson also began a four-month suspension from practicing medicine in the UK.) 

Peter Wilmshurst: In part, because I was pleased that he was shown to be dishonest, because I knew that he was, which was why I reported him. But I wasn’t pleased in the sense that I don’t think the investigation dealt with all the issues involved in the Migraine Intervention with STARflex Technology (MIST) Trial.

RW: What additional issues did you hope to see addressed? Continue reading My life as a whistleblower: Q&A with Peter Wilmshurst

Voinnet retracts highly cited paper, bringing his total to 7

coverOlivier Voinnet, a well-known plant scientist at the ETH in Zurich, has notched his 7th retraction for a highly cited paper. The 2003 paper was pulled when “additional image manipulations” came to light after The Plant Journal issued a correction earlier this year.

The retraction follows an investigation into — and then retraction of — several other papers co-authored by Voinnet. The authors originally corrected the paper after they learned one image had been duplicated, and repeating the experiment found the “same interpretation and conclusions” held true. But when the corresponding author learned of additional “data manipulation,” they decided to retract the paper altogether.

Here’s the retraction notice for “An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus:”

Continue reading Voinnet retracts highly cited paper, bringing his total to 7